Apex Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Apex Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$40.5M	Buy	310,410 +6,426	+2%	+$800K	0.89%	48
2015 Q4	$42.7M	Sell	303,984 -1,307	-0.4%	-$181K	0.95%	41
2015 Q3	$40.5M	Buy	305,291 +11,637	+4%	+$2M	0.92%	44
2015 Q2	$51.7M	Buy	293,654 +14,248	+5%	+$2.56M	1.11%	38
2015 Q1	$48.3M	Buy	279,406 +15,691	+6%	+$2.69M	1.14%	35
2014 Q4	$43.2M	Buy	263,715 +12,946	+5%	+$2.15M	1.15%	32
2014 Q3	$40.3M	Buy	250,769 +71,577	+40%	+$11M	1.21%	33
2014 Q2	$26.3M	Buy	179,192 +106,025	+145%	+$14.7M	0.81%	57
2014 Q1	$10.1M	Sell	73,167 -184,178	-72%	-$27.7M	0.36%	77
2013 Q4	$32.6M	Sell	257,345 -22,654	-8%	-$2.34M	1.22%	27
2013 Q3	$25.8M	Buy	+279,999	New	+$22.6M	1.13%	37

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Apex Capital Management's JAZZ Position: Q1 2016 in Review

Apex Capital Management increased its Jazz Pharmaceuticals (JAZZ) stake by 2.1% in Q1 2016, buying an estimated $800K and bringing the position to 310,410 shares worth $40.5M. The position accounts for 0.89% of the portfolio, ranked #48.

Apex Capital Management first reported a position in JAZZ in Q3 2013 and has held it in 11 quarters since. The position peaked at $51.7M in Q2 2015. 339 funds tracked by Wall St. Rank hold JAZZ as of Q1 2016.

Apex Capital Management held 310,410 shares of Jazz Pharmaceuticals worth $40.5M as of Q1 2016.
Apex Capital Management bought 6,426 Jazz Pharmaceuticals shares in Q1 2016, an estimated $800K.
Jazz Pharmaceuticals made up 0.89% of Apex Capital Management's portfolio in Q1 2016, its #48 holding.
Apex Capital Management first reported a position in Jazz Pharmaceuticals in Q3 2013 and has held it in 11 quarters since.
Apex Capital Management's Jazz Pharmaceuticals position peaked at $51.7M in Q2 2015.
339 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.